Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
January 26 2021 - 8:59AM
Edgar (US Regulatory)
Novartis AG
PO Box
CH 4002 Basel
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
January 26, 2021
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on January 26, 2021.
Respectfully submitted,
Novartis AG
/s/ SHANNON THYME KLINGER
|
/s/ HARRY KIRSCH
|
Shannon Thyme Klinger
|
Harry Kirsch
|
Chief Legal Officer
|
Chief Financial Officer
|
of Novartis
|
of Novartis
|
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024